1. Technical Field
The present disclosure relates generally to treating a wound by applying negative pressure to the wound, and, more specifically, to a portable negative pressure wound therapy system for treating a wound.
2. Description of Related Art
Wound closure involves the migration of epithelial and subcutaneous tissue adjacent the wound towards the center and away from the base of the wound until the wound closes. Unfortunately, closure is difficult with large wounds, chronic wounds or wounds that have become infected. In such wounds, a zone of stasis (i.e. an area in which localized swelling of tissue restricts the flow of blood to the tissues) forms near the surface of the wound. Without sufficient blood flow, the epithelial and subcutaneous tissues surrounding the wound not only receive diminished oxygen and nutrients, but, are also less able to successfully fight microbial infection and, thus, are less able to close the wound naturally. Such wounds have presented difficulties to medical personnel for many years.
Negative pressure wound therapy (NPWT), also known as suction or vacuum therapy, has been used in treating and healing wounds. Application of negative pressure, e.g. reduced or sub-atmospheric pressure, to a localized reservoir over a wound has been found to assist in closing the wound by promoting blood flow to the area, stimulating the formation of granulation tissue, and encouraging the migration of healthy tissue over the wound. Negative pressure may also inhibit bacterial growth by drawing fluids from the wound such as exudates, which may tend to harbor bacteria. This technique has proven particularly effective for chronic or healing-resistant wounds, and is also used for other purposes such as post-operative wound care.
Generally, negative pressure therapy provides for a wound covering to be positioned over the wound to facilitate suction at the wound area. A conduit is introduced through the wound covering to provide fluid communication to an external vacuum source. Atmospheric gas, wound exudates, or other fluids may thus be drawn from the reservoir through the fluid conduit to stimulate healing of the wound. Exudates drawn from the reservoir may be deposited in a collection canister.
Often, a portable NPWT device is worn by the patient so that the patient may remain ambulatory instead of being confined to a stationary position. While a patient is ambulatory, the portable NPWT device tends to tip or tilt in a multitude of directions. If there are enough exudates in the collection canister, the exudates may cover a suction port leading from the vacuum source to the collection canister because fluid
In addition, portable NPWT devices have a control unit attached to the canister. The control unit generally contains the suction pump and sensitive electronics such as a pressure transducers, microprocessors, or the like. When the NPWT device tips, exudate may aspirate from the canister into the control unit thereby damaging the suction pump and/or electronic components.
The present disclosure relates to a portable NPWT system including a dressing assembly for positioning over a wound to apply a negative pressure to the wound and a canister assembly. The canister assembly includes a control unit having a vacuum source and a controller and a collection canister in communication with the dressing assembly operable to receive fluid from the wound. The collection canister has ports to introduce a vacuum from the vacuum source into the collection canister. A ball float is provided to substantially close the suction port in response to one of collection of a predetermined volume of exudate in the collection canister, tilting of the collection canister beyond a predetermined angle of orientation or inversion of the collection canister.
The present disclosure also relates to a portable NPWT system including a dressing assembly for positioning over a wound to apply a negative pressure to the wound and a canister assembly. The canister assembly includes a control unit having a vacuum source and a controller and a collection canister in communication with the dressing assembly operable to receive fluid from the wound. The collection canister has ports to introduce a vacuum from the vacuum source into the collection canister. A closure valve mounted adjacent to the suction port is provided and is adapted to move from an open position where the negative pressure source is capable of drawing a vacuum in the collection canister through the suction port and a closed position where the suction port is substantially closed in response to one of collection of a predetermined volume of exudate in the collection canister, tilting of the collection canister beyond a predetermined angle of orientation or inversion of the collection canister.
Various embodiments of the wound dressing system of the present disclosure are described herein with reference to the drawings wherein:
Various embodiments of the present disclosure provide NPWT systems (or apparatus) including a collection canister having a chamber to collect wound fluids. Embodiments of the presently disclosed NPWT systems are generally suitable for use in applying negative pressure to a wound to facilitate healing of the wound in accordance with various treatment modalities. Embodiments of the presently disclosed NPWT systems are entirely portable and may be worn or carried by the user such that the user may be completely ambulatory during the therapy period. Embodiments of the presently disclosed NPWT apparatus and components thereof may be entirely reusable or may be entirely disposable after a predetermined period of use or may be individually disposable whereby some of the components are reused for a subsequent therapy application.
Hereinafter, embodiments of the presently disclosed NPWT systems and embodiments of the presently disclosed sensors for use in NPWT systems will be described with reference to the accompanying drawings. Like reference numerals may refer to similar or identical elements throughout the description of the figures. As used herein, “wound exudate”, or, simply, “exudate”, generally refers to any fluid output from a wound, e.g., blood, serum, and/or pus, etc. As used herein, “fluid” generally refers to a liquid, a gas or both.
Referring to
Contact layer 18 is intended for placement within the wound bed “w” and may be relatively non-supportive or flexible to substantially conform to the topography of the wound bed “w”. A variety of materials may be used for the contact layer 18. Contact layer 18 selection may depend on various factors such as the patient's condition, the condition of the periwound skin, the amount of exudate and/or the condition of the wound bed “w”. Contact layer 18 may be formed from perforated film material. The porous characteristic of the contact layer 18 permits exudate to pass from the wound bed “w” through the contact layer 18. Passage of wound exudate through the contact layer 18 may be substantially unidirectional such that exudate does not tend to flow back into the wound bed “w”. Unidirectional flow may be encouraged by directional apertures, e.g., apertures positioned at peaks of undulations or cone-shaped formations protruding from the contact layer 18. Unidirectional flow may also be encouraged by laminating the contact layer 18 with materials having absorption properties differing from those of the contact layer 18, or by selection of materials that promote directional flow. A non-adherent material may be selected for forming the contact layer 18 such that the contact layer 18 does not tend to cling to the wound bed “w” or surrounding tissue when it is removed. One example of a material that may be suitable for use as a contact layer 18 is commercially available under the trademark XEROFLOW® offered by Tyco Healthcare Group LP (d/b/a Covidien). Another example of a material that may be suitable for use as the contact layer 18 is the commercially available CURITY® non-adherent dressing offered by Tyco Healthcare Group LP (d/b/a Covidien).
Wound filler 20 is positioned in the wound bed “w” over the contact layer 18 and is intended to transfer wound exudate. Wound filler 20 is conformable to assume the shape of any wound bed “w” and may be packed up to any level, e.g., up to the level of healthy skin “s” or to overfill the wound such that wound filler 20 protrudes over healthy skin “s”. Wound filler 20 may be treated with agents such as polyhexamethylene biguanide (PHMB) to decrease the incidence of infection and/or other medicaments to promote wound healing. A variety of materials may be used for the wound filler 20. An example of a material that may be suitable for use as the wound filler 20 is the antimicrobial dressing commercially available under the trademark KERLIX™ AMD offered by Tyco Healthcare Group LP (d/b/a Covidien).
Cover layer 24 may be formed of a flexible membrane, e.g., a polymeric or elastomeric film, which may include a biocompatible adhesive on at least a portion of the cover layer 24, e.g., at the periphery 26 of the cover layer 24. Alternately, the cover layer 24 may be a substantially rigid member. Cover layer 24 may be positioned over the wound bed “w” such that a substantially continuous band of a biocompatible adhesive at the periphery 26 of the cover layer 24 forms a substantially fluid-tight seal with the surrounding skin “s”. An example of a material that may be suitable for use as the cover layer 24 is commercially available under the trademark CURAFORM ISLAND® offered by Tyco Healthcare Group LP (d/b/a Covidien).
Cover layer 24 may act as both a microbial barrier and a fluid barrier to prevent contaminants from entering the wound bed “w” and to help maintain the integrity thereof.
In one embodiment, the cover layer 24 is formed from a moisture vapor permeable membrane, e.g., to promote the exchange of oxygen and moisture between the wound bed “w” and the atmosphere. An example of a membrane that may provide a suitable moisture vapor transmission rate (MVTR) is a transparent membrane commercially available under the trade name POLYSKIN®II offered by Tyco Healthcare Group LP (d/b/a Covidien). A transparent membrane may help to permit a visual assessment of wound conditions to be made without requiring removal of the cover layer 24.
Wound dressing 12 may include a vacuum port 30 having a flange 34 to facilitate connection of the vacuum chamber 14 to a vacuum system. Vacuum port 30 may be configured as a rigid or flexible, low-profile component and may be adapted to receive a conduit 36 in a releasable and fluid-tight manner. An adhesive on at least a portion of the underside of the flange 34 may be used to provide a mechanism for affixing the vacuum port 30 to the cover layer 24. The relative positions, size and/or shape of the vacuum port 30 and the flange 34 may be varied from an embodiment depicted in
Any suitable conduit may be used for the conduit 36, including conduit fabricated from flexible elastomeric or polymeric materials. In the NPWT apparatus 10 illustrated in
The first, second, third and fourth conduit sections 36A, 36B, 36C and 36D of the conduit 36 may be connected to components of the apparatus 10 by conventional air-tight means, such as, for example, friction fit, bayonet coupling, or barbed connectors. The connections may be made permanent. Alternately, a quick-disconnect or other releasable connection means may be used to provide some adjustment flexibility to the apparatus 10.
Collection canister 38 may be formed of any type of container that is suitable for containing wound fluids. For example, a semi-rigid plastic bottle may be used for the collection canister 38. A flexible polymeric pouch or other hollow container body may be used for the collection canister 38. Collection canister 38 may contain an absorbent material to consolidate or contain the wound fluids or debris. At least a portion of canister 38 may be transparent. e.g. to permit a visual assessment of the wound exudate to assist in evaluating the color, quality and/or quantity of exudate. A transparent portion of the collection canister 38 may permit a visual assessment to assist in determining the remaining capacity or open volume of the canister and/or may assist in determining whether to replace the collection canister 38.
The collection canister 38 is in fluid communication with the wound dressing 12 via the first and second conduit sections 36A, 36B. The third and fourth conduit sections 36C, 36D connect the collection canister 38 to the vacuum source 40 that generates or otherwise provides a negative pressure to the collection canister 38. Vacuum source 40 may include a peristaltic pump, a diaphragmatic pump or other suitable mechanism. Vacuum source 40 may be a miniature pump or micropump that may be biocompatible and adapted to maintain or draw adequate and therapeutic vacuum levels. The vacuum level of subatmospheric pressure achieved may be in the range of about 20 mmHg to about 500 mmHg. In embodiments, the vacuum level may be about 75 mmHg to about 125 mmHg, or about 40 mmHg to about 80 mmHg. One example of a peristaltic pump that may be used as the vacuum source 40 is the commercially available Kangaroo PET Eternal Feeding Pump offered by Tyco Healthcare Group LP (d/b/a Covidien). Vacuum source 40 may be actuated by an actuator (not shown) which may be any means known by those skilled in the art, including, for example, alternating current (AC) motors, direct current (DC) motors, voice coil actuators, solenoids, and the like. The actuator may be incorporated within the vacuum source 40.
In embodiments, the NPWT apparatus 10 includes one or more fluid line couplings 100 that allow for selectable coupling and decoupling of conduit sections. For example, a fluid line coupling 100 may be used to maintain fluid communication between the first and second conduit sections 36A, 36B when engaged, and may interrupt fluid flow between the first and second conduit sections 36A, 36B when disengaged. Thus, fluid line coupling 100 may facilitate the connection, disconnection or maintenance of components of the NPWT apparatus 10, including the replacement of the collection canister 38. Additional or alternate placement of one or more fluid line couplings 100 at any location in line with the conduit 36 may facilitate other procedures. For example, the placement of a fluid line coupling 100 between the third and fourth conduit sections 36C, 36D, as depicted in
Referring to
Canister assembly 240 includes a control unit 246 and a collection canister 242 disposed below the control unit 246. Control unit 246 may be reusable and collection canister 242 may be disposable. Control unit 246 and the collection canister 242 may be releasably coupled. Mechanisms for selective coupling and decoupling of the control unit 246 and the collection canister 242 include fasteners, latches, clips, straps, bayonet mounts, magnetic couplings, and other devices. Collection canister 242 may consist of any container suitable for containing wound fluids.
In one embodiment, the NPWT system 200 is capable of operating in a continuous mode or an alternating mode. In the continuous mode, the control unit 246 controls a pump to continuously supply a selected vacuum level at the collection canister 242 to create a reduced pressure state within the dressing assembly 210. In the alternating mode, the control unit 246 controls the pump to alternating supply a first negative pressure, e.g., about 80 mmHg, at the collection canister 242 for a preset fixed amount of time and a second negative pressure, e.g., about 50 mmHg, at the collection canister 242 for a different preset fixed amount of time.
In general, the output of the pump is directly related to the degree of air leakage in the NPWT system 200 and the open volume in the collection canister 242. If there is sufficient air leakage in the system 200, e.g., at the dressing assembly 210, the pump can remain on continuously and the control unit 246 can control negative pressure at the collection canister 242 by adjusting the pump speed. Alternatively, if there is not sufficient air leakage in the system 200 to permit the pump to remain on continuously, the control unit 246 can control negative pressure at the collection canister 242 by turning the pump on and off, e.g., for non-equal on/off periods of time.
Canister assembly 240 may be constructed from a variety of materials such as Lucite™ polycarbonate, metals, metal alloys, plastics, or other durable materials capable of withstanding forces applied during normal use, and may have some capability of withstanding possibly excessive forces resulting from misuse. Collection canister 242 may include a window with fluid level markings or for promoting visual assessment of the amount of exudate contained within the collection canister 242. A transparent or partially transparent collection canister 242 may thus assist in determining the remaining capacity of the collection canister 242 and/or when the collection canister 242 should be replaced.
Referring to
Controller 310 controls a vacuum source 320 based on the mode of therapy selected as well as inputs received from pressure transducer 330 and pressure transducer 330. Vacuum source 320 may be a miniature pump or micropump that may be biocompatible and adapted to maintain or draw adequate and therapeutic vacuum levels. The vacuum level of subatmospheric pressure achieved may be in the range of about 20 mmHg to about 500 mmHg. In embodiments, the vacuum level may be about 75 mmHg and about 125 mmHg, or between about 30 mmHg and 80 mmHg. Vacuum source 320 is actuated by an actuator which may be any means known by those skilled in the art, including, for example, AC motors, DC motors, voice coil actuators, solenoids, etc.
Controller 310 maintains a selected vacuum level at the canister 242 by monitoring the pressure in the canister 242 using pressure transducer 330. If the vacuum level in the canister 242 exceeds a threshold as measured by pressure transducer 340, the controller 310 turns the vacuum source 320 off or reduces the output of the vacuum source 320 to reduce the vacuum level in the canister 242. If the vacuum level in the canister 242 falls below a threshold as measured by pressure transducer 340, the controller 310 turns the vacuum source 320 on or increases the output of the vacuum source 320 to increase the vacuum level in the canister 242.
Controller 310 also controls operation of the vacuum source 320 based on the output of pressure transducer 340. Pressure transducer 340, which could be a pressure switch, monitors the pressure at the inlet of the vacuum source 320 to determine a pressure spike indicative of the replace canister condition which will be described in more detail below. Alternately, if a pressure switch is used, once a threshold of negative pressure is reached, it will actuate thereby signaling the controller 310 to turn the vacuum source 320 off.
Control system 300 may include a speaker 350 to produce an audible indication to notify the user of a condition, e.g., leak, canister assembly tip, failed pressure sensor, failed pump, excessive vacuum, or low battery conditions. The control system 300 may also include a display 360 to notify a user of an alarm condition, a state of the NPWT device, or other information related to the treatment of a wound by the NPWT device. Display 360 may be a liquid crystal display (LCD), a light emitting diode (LED) display, or any number of LEDs, neon lamps, incandescent bulbs, or the like.
Control system 300 responds to various sensed events by signaling alarms. Various types of conditions may be signaled by alarms. In embodiments, control system 300 is capable of signaling alarms for failed pressure sensor condition, use odometer expired condition, watchdog reset condition, failed pump condition, leak condition, replace canister condition, excessive vacuum condition, failed LEDs condition, low battery condition, very low battery condition, and failed battery condition. Priority levels may be associated with alarms. In embodiments, the priority levels of alarms are low priority alarm, medium priority alarm, and system alarm (highest priority). Low priority alarms, when triggered, may be continuously indicated. Medium priority alarms and system alarms, when triggered, may have a flashing indication.
Control system 300 may stop operation of the in response to an alarm, e.g., depending on alarm type and/or priority level. In embodiments, the control system 300 stops operation of the pump in response to system alarms, e.g., failed pressure sensor system alarm, use odometer expired system alarm, watchdog reset system alarm, failed pump system alarm, excessive vacuum system alarm, and/or failed LEDs system alarm.
If an air leak develops in the NPWT system 200, e.g., at the dressing assembly 210, for which the control unit 246 cannot compensate by increasing the pump speed, the control system 300 may indicate an alarm. For example, the control system 300 may indicate a leak alarm after two consecutive minutes of operation in which the vacuum level is below the current set point (or below the minimum level of a set point range).
In embodiments, the control system 300 includes a user interface (not shown) which may be incorporated into the display 360 or may be a set of user actuated switches or buttons. The user turns ON the canister assembly 240 by pressing a power button (not shown). When the power button is pressed, the control system 300 performs a series of internal checks during power up. In one embodiment, after successfully completing the power-up tasks, the control system 300 turns on the pump 320 using the stored settings. At initial activation of the canister assembly 240, the stored settings are the default settings. In one embodiment, the default settings for controlling the pump 320 are 80 mmHg and continuous mode. In one embodiment, the currently stored vacuum level setting can be altered by the user, e.g., to 50 mmHg. In one embodiment, the currently stored mode setting can be altered by the user, e.g., to an alternating mode.
Referring to
Pressure transducer 330 has a hydrophobic filter at area 404, which protects the pressure transducer 330 if exudate fluid entered a pressure transducer tube (not shown). The pressure transducer is attached to the hydrophobic filter at area 404 and the opposite end of the pressure transducer tube attaches to a transducer port 503 (shown in
A pressure transducer 340 (shown in
A direct current (DC) motor-driven pump 410 is contained within the control unit 246. A vibration damping tape, e.g., visco-elastic damping tape, may be applied to the outer surface of the pump 410 to reduce vibration and its associated noise. The pump 410 may be contained within its own sub-housing 414 which may be hollow or formed entirely of open cell molded foam, e.g., used as a silencer to provide sound mitigation by reducing the sound energy of the expelled air during operation. As part of the sound mitigation arrangement, a tube may be fitted to the pump sub-housing 414.
A pump inlet tube 408 is attached on one end to the inlet port 412 of the pump 410 on one end. The other end of the pump inlet tube 408 attaches to the filter assembly 416. The filter assembly 416 has an orifice 418. A suction chamber is located directly below the filter assembly 416 that receives the canister suction port 601 (shown in
When the ball float 706 contacts the seat 708, air flow to the pump 410 is blocked while the pump 410 continues to run, thereby producing the pressure spike mentioned, which indicates the replace canister condition. A fixed leak is incorporated either into the pump 410 or to the pump inlet tube 408, which is meant to relieve the negative pressure at the pump inlet and at the floating ball seat 708, so that the floating ball 706 can fall out of the sealing position.
Power source 828 may be disposed within housing 810 or separately mountable to the housing 810. A suitable power source 828 includes alkaline batteries, wet cell batteries, dry cell batteries, nickel cadmium batteries, solar generated means, lithium batteries, NiMH batteries (nickel metal hydride) each of which may be of the disposable or rechargeable variety.
Housing 810 further includes vent portal 830 configured to vent exhaust air from vacuum source 824 through exhaust port 832. Vent portal 830 extends from housing 810 and may be directly connected to vacuum source 824. It is also envisions that vent portal 830 may exhaust air from within housing 810 rather than directly from vacuum source 824. Exhaust port 832 may include filter 834 extending across the exhaust port 832. Filter 834 may be a bacterial filter to prevent emission of bacteria from housing 810.
Collection canister 814 collects exudates “e” removed from the wound bed “w’ during therapy through conduit, or tubing, 806. Collection canister 814 is associated with housing 810 and may be incorporated within the housing 810 or releasably connected to the housing 810 by conventional means. Housing 810 and collection canister 814 of canister assembly 800 may be releasably coupled. Mechanisms for selective coupling and decoupling of housing 810 and collection canister 814 include fasteners, latches, clips, straps, bayonet mounts, magnetic couplings, and other devices.
Collection canister 814 may comprise any container suitable for containing wound fluids and is substantially rigid defining an internal chamber 836 in fluid communication with tubing 806. Collection canister 814 may contain an absorbent material to consolidate or contain the wound drainage or debris. In embodiments, at least a portion of collection canister 814 may be transparent to assist in evaluating the color, quality, or quantity of wound exudates. A transparent canister may thus assist in determining the remaining capacity of the canister or when the canister should be replaced. In the alternative, collection canister 814 may be relatively flexible.
Collection canister 814 includes fluid inlet 838 and suction port 840. Fluid inlet 838 is configured to operably engage conduit 806. Fluid inlet 838 may be connectable with conduit 806 by conventional air and fluid tight means, such as those described above. In embodiments, fluid inlet 838 may contain a luer lock or other connector within the purview of those skilled in the art to secure the end of conduit 806 with the fluid inlet 838. It is envisioned that fluid inlet 838 is configured to receive a cap in order to prevent leakage of exudates and odor from internal chamber 836 of collection canister 814 when housing 810 is separated from the canister 814.
Suction port 840 is in fluid communication with vacuum source 824 and may be an opening defined in a wall of housing 810. A filter 842, such as a hydrophobic membrane or baffling to prevent exudates from being aspirated into pump 810 may be disposed adjacent or within suction port 840. Filter 842 may also include charcoal or other odor absorbing materials and may prevent the passage of bacteria. Pump 824 creates a vacuum within internal chamber 836 of collection canister 832 by drawing air through suction port 840.
Collection canister 814 includes closure valve 844. Closure valve 844 is pivotally mounted about hinge 846 which is connected to internal chamber surface of collection canister 814. Closure valve 844 assumes the open position depicted in
Closure valve 844 prevents exudates from clogging and/or entering pump 824 or control unit 812 when collection canister 814 is in an inverted or a tilted position. For example, when collection canister 844 is tilted beyond a predetermined orientation, e.g., when on its side or inverted with suction port 840 facing in a general downward direction, closure valve 844 moves under its own weight, the weight of exudates, and/or gravity to a closed position. Moreover, when tilted or inverted, closure valve 844 defines a moment arm thereby causing the closure valve 844 to pivot about hinge 846 from the open position to the closed position (
In the closed position of
While the disclosure has been illustrated and described, it is not intended to be limited to the details shown, since various modifications and substitutions can be made without departing in any way from the spirit of the present disclosure. As such, further modifications and equivalents of the invention herein disclosed can occur to persons skilled in the art using no more than routine experimentation, and all such modifications and equivalents are believed to be within the spirit and scope of the disclosure as defined by the following claims.
The present invention claims the benefit of and priority to U.S. provisional patent Application Ser. No. 61/078,838, filed on Jul. 8, 2008, disclosure of which may be referred to herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3026874 | Stevens | Mar 1962 | A |
3367332 | Groves | Feb 1968 | A |
3486504 | Austin, Jr. | Dec 1969 | A |
3572340 | Lloyd et al. | Mar 1971 | A |
3712298 | Snowdon et al. | Jan 1973 | A |
3809086 | Schachet et al. | May 1974 | A |
3874387 | Barbieri | Apr 1975 | A |
3980166 | DeFeudis | Sep 1976 | A |
4063556 | Thomas et al. | Dec 1977 | A |
4080970 | Miller | Mar 1978 | A |
4112947 | Nehring | Sep 1978 | A |
4112949 | Rosenthal et al. | Sep 1978 | A |
4136696 | Nehring | Jan 1979 | A |
4202331 | Yale | May 1980 | A |
4224945 | Cohen | Sep 1980 | A |
4228798 | Deaton | Oct 1980 | A |
4266545 | Moss | May 1981 | A |
4280680 | Payne | Jul 1981 | A |
4382441 | Svedman | May 1983 | A |
4510802 | Peters | Apr 1985 | A |
4524064 | Nambu | Jun 1985 | A |
4538645 | Perach | Sep 1985 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4700479 | Saito et al. | Oct 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4738257 | Meyer et al. | Apr 1988 | A |
4743232 | Kruger | May 1988 | A |
4870975 | Cronk et al. | Oct 1989 | A |
4874363 | Abell | Oct 1989 | A |
4969880 | Zamierowski | Nov 1990 | A |
4990137 | Graham | Feb 1991 | A |
4997438 | Nipper | Mar 1991 | A |
5071409 | Rosenberg | Dec 1991 | A |
5100395 | Rosenberg | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5106629 | Cartmell et al. | Apr 1992 | A |
5135485 | Cohen et al. | Aug 1992 | A |
5141503 | Sewell, Jr. | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5152757 | Eriksson | Oct 1992 | A |
5160322 | Scheremet et al. | Nov 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5178157 | Fanlo | Jan 1993 | A |
5180375 | Feibus | Jan 1993 | A |
5195977 | Pollitt | Mar 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5263922 | Sova et al. | Nov 1993 | A |
D364679 | Heaton et al. | Nov 1995 | S |
5484427 | Gibbons | Jan 1996 | A |
5527293 | Zamierowski | Jun 1996 | A |
5536233 | Khouri | Jul 1996 | A |
5549584 | Gross | Aug 1996 | A |
5588958 | Cunningham et al. | Dec 1996 | A |
5624374 | Von Iderstein | Apr 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5678564 | Lawrence et al. | Oct 1997 | A |
5701917 | Khouri | Dec 1997 | A |
5733305 | Fleischmann | Mar 1998 | A |
5779657 | Daneshvar | Jul 1998 | A |
5787928 | Allen et al. | Aug 1998 | A |
5840049 | Tumey et al. | Nov 1998 | A |
5911222 | Lawrence et al. | Jun 1999 | A |
5944703 | Dixon et al. | Aug 1999 | A |
5960837 | Cude | Oct 1999 | A |
6010524 | Fleischmann | Jan 2000 | A |
6071267 | Zamierowski | Jun 2000 | A |
6117111 | Fleischmann | Sep 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
D434150 | Tumey et al. | Nov 2000 | S |
6142982 | Hunt et al. | Nov 2000 | A |
6174306 | Fleischmann | Jan 2001 | B1 |
6203563 | Fernandez | Mar 2001 | B1 |
6261276 | Reitsma | Jul 2001 | B1 |
6325788 | McKay | Dec 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6348423 | Griffiths et al. | Feb 2002 | B1 |
6395955 | Roe et al. | May 2002 | B1 |
6398767 | Fleischmann | Jun 2002 | B1 |
6406447 | Thrash et al. | Jun 2002 | B1 |
6420622 | Johnston et al. | Jul 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6500112 | Khouri | Dec 2002 | B1 |
D469175 | Hall et al. | Jan 2003 | S |
D469176 | Hall et al. | Jan 2003 | S |
6520982 | Boynton et al. | Feb 2003 | B1 |
6547255 | Donaway et al. | Apr 2003 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
D475134 | Randolph | May 2003 | S |
6557704 | Randolph | May 2003 | B1 |
D478659 | Hall et al. | Aug 2003 | S |
6607495 | Skalak et al. | Aug 2003 | B1 |
6626891 | Ohmstede | Sep 2003 | B2 |
6648862 | Watson | Nov 2003 | B2 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6695823 | Lina et al. | Feb 2004 | B1 |
6695824 | Howard et al. | Feb 2004 | B2 |
D488558 | Hall | Apr 2004 | S |
6752794 | Lockwood et al. | Jun 2004 | B2 |
6755807 | Risk, Jr. et al. | Jun 2004 | B2 |
6764462 | Risk, Jr. et al. | Jul 2004 | B2 |
6767334 | Randolph | Jul 2004 | B1 |
6800074 | Henley et al. | Oct 2004 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
6824533 | Risk, Jr. et al. | Nov 2004 | B2 |
6855135 | Lockwood et al. | Feb 2005 | B2 |
6855860 | Ruszczak et al. | Feb 2005 | B2 |
6856821 | Johnson | Feb 2005 | B2 |
6887228 | McKay | May 2005 | B2 |
6887263 | Bleam et al. | May 2005 | B2 |
6936037 | Bubb et al. | Aug 2005 | B2 |
6942633 | Odland | Sep 2005 | B2 |
6942634 | Odland | Sep 2005 | B2 |
6951553 | Bubb et al. | Oct 2005 | B2 |
6960181 | Stevens | Nov 2005 | B2 |
6979324 | Bybordi et al. | Dec 2005 | B2 |
6994702 | Johnson | Feb 2006 | B1 |
7022113 | Lockwood et al. | Apr 2006 | B2 |
7037254 | O'Connor et al. | May 2006 | B2 |
7052167 | Vanderschuit | May 2006 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7077832 | Fleischmann | Jul 2006 | B2 |
7108683 | Zamierowski | Sep 2006 | B2 |
7117869 | Heaton et al. | Oct 2006 | B2 |
7128719 | Rosenberg | Oct 2006 | B2 |
7128735 | Weston | Oct 2006 | B2 |
7144390 | Hannigan et al. | Dec 2006 | B1 |
7169151 | Lytinas | Jan 2007 | B1 |
7182758 | McCraw | Feb 2007 | B2 |
7195624 | Lockwood et al. | Mar 2007 | B2 |
7198046 | Argenta et al. | Apr 2007 | B1 |
7214202 | Vogel et al. | May 2007 | B1 |
7216651 | Argenta et al. | May 2007 | B2 |
D544092 | Lewis | Jun 2007 | S |
7273054 | Heaton et al. | Sep 2007 | B2 |
7276051 | Henley et al. | Oct 2007 | B1 |
7279612 | Heaton et al. | Oct 2007 | B1 |
7316672 | Hunt et al. | Jan 2008 | B1 |
D565177 | Locke et al. | Mar 2008 | S |
7338482 | Lockwood et al. | Mar 2008 | B2 |
7351250 | Zamierowski | Apr 2008 | B2 |
7361184 | Joshi | Apr 2008 | B2 |
7381211 | Zamierowski | Jun 2008 | B2 |
7381859 | Hunt et al. | Jun 2008 | B2 |
7396345 | Knighton et al. | Jul 2008 | B2 |
7410495 | Zamierowski | Aug 2008 | B2 |
7413570 | Zamierowski | Aug 2008 | B2 |
7413571 | Zamierowski | Aug 2008 | B2 |
7422576 | Boynton et al. | Sep 2008 | B2 |
20010020145 | Satterfield et al. | Sep 2001 | A1 |
20010031943 | Urie | Oct 2001 | A1 |
20010043943 | Coffey | Nov 2001 | A1 |
20020016577 | Ohmstede | Feb 2002 | A1 |
20020108614 | Schultz | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20020151836 | Burden | Oct 2002 | A1 |
20020161346 | Lockwood et al. | Oct 2002 | A1 |
20020198504 | Risk, Jr. et al. | Dec 2002 | A1 |
20030078532 | Ruszczak et al. | Apr 2003 | A1 |
20030093041 | Risk, Jr. et al. | May 2003 | A1 |
20030181850 | Diamond et al. | Sep 2003 | A1 |
20030208149 | Coffey | Nov 2003 | A1 |
20030212357 | Pace | Nov 2003 | A1 |
20030212359 | Butler | Nov 2003 | A1 |
20030219469 | Johnson et al. | Nov 2003 | A1 |
20040006319 | Lina et al. | Jan 2004 | A1 |
20040030304 | Hunt et al. | Feb 2004 | A1 |
20040039415 | Zamierowski | Feb 2004 | A1 |
20040064111 | Lockwood et al. | Apr 2004 | A1 |
20040064132 | Boehringer et al. | Apr 2004 | A1 |
20040073151 | Weston | Apr 2004 | A1 |
20040093026 | Weidenhagen et al. | May 2004 | A1 |
20040113309 | Thompson, Jr. et al. | Jun 2004 | A1 |
20040122434 | Argenta et al. | Jun 2004 | A1 |
20040167482 | Watson | Aug 2004 | A1 |
20040193218 | Butler | Sep 2004 | A1 |
20040241213 | Bray | Dec 2004 | A1 |
20040243073 | Lockwood et al. | Dec 2004 | A1 |
20040249353 | Risks, Jr. et al. | Dec 2004 | A1 |
20040260230 | Randolph | Dec 2004 | A1 |
20050004534 | Lockwood et al. | Jan 2005 | A1 |
20050010153 | Lockwood et al. | Jan 2005 | A1 |
20050020955 | Sanders et al. | Jan 2005 | A1 |
20050070835 | Joshi | Mar 2005 | A1 |
20050070858 | Lockwood et al. | Mar 2005 | A1 |
20050085795 | Lockwood et al. | Apr 2005 | A1 |
20050090787 | Risk, Jr. et al. | Apr 2005 | A1 |
20050101940 | Radl et al. | May 2005 | A1 |
20050107756 | McCraw | May 2005 | A1 |
20050131327 | Lockwood et al. | Jun 2005 | A1 |
20050137539 | Biggie et al. | Jun 2005 | A1 |
20050147562 | Hunter et al. | Jul 2005 | A1 |
20050177190 | Zamierowski | Aug 2005 | A1 |
20050182445 | Zamierowski | Aug 2005 | A1 |
20050222527 | Miller et al. | Oct 2005 | A1 |
20050222544 | Weston | Oct 2005 | A1 |
20050261642 | Weston | Nov 2005 | A1 |
20050261643 | Bybordi et al. | Nov 2005 | A1 |
20060015087 | Risk, Jr. et al. | Jan 2006 | A1 |
20060025727 | Boehringer et al. | Feb 2006 | A1 |
20060029650 | Coffey | Feb 2006 | A1 |
20060039742 | Cable, Jr. et al. | Feb 2006 | A1 |
20060041247 | Petrosenko et al. | Feb 2006 | A1 |
20060079852 | Bubb et al. | Apr 2006 | A1 |
20060100586 | Karpowicz et al. | May 2006 | A1 |
20060100594 | Adams et al. | May 2006 | A1 |
20060116620 | Oyaski | Jun 2006 | A1 |
20060149170 | Boynton et al. | Jul 2006 | A1 |
20070005028 | Risk, Jr. et al. | Jan 2007 | A1 |
20070014837 | Johnson et al. | Jan 2007 | A1 |
20070016152 | Karpowicz | Jan 2007 | A1 |
20070021697 | Ginther et al. | Jan 2007 | A1 |
20070027414 | Hoffman et al. | Feb 2007 | A1 |
20070032754 | Walsh | Feb 2007 | A1 |
20070032755 | Walsh | Feb 2007 | A1 |
20070032778 | Heaton et al. | Feb 2007 | A1 |
20070055209 | Patel et al. | Mar 2007 | A1 |
20070066946 | Haggstrom et al. | Mar 2007 | A1 |
20070078366 | Haggstrom et al. | Apr 2007 | A1 |
20070078432 | Halseth et al. | Apr 2007 | A1 |
20070167927 | Hunt et al. | Jul 2007 | A1 |
20070179460 | Adahan | Aug 2007 | A1 |
20070185426 | Ambrosio et al. | Aug 2007 | A1 |
20070219513 | Lina et al. | Sep 2007 | A1 |
20070225663 | Watt et al. | Sep 2007 | A1 |
20070233022 | Henley et al. | Oct 2007 | A1 |
20070265585 | Joshi et al. | Nov 2007 | A1 |
20080011667 | Ruschke | Jan 2008 | A1 |
20080071235 | Locke et al. | Mar 2008 | A1 |
20080082059 | Fink et al. | Apr 2008 | A1 |
20080103462 | Wenzel et al. | May 2008 | A1 |
20080132819 | Radl et al. | Jun 2008 | A1 |
20080167593 | Fleischmann | Jul 2008 | A1 |
20080183233 | Koch et al. | Jul 2008 | A1 |
20080200857 | Lawhorn | Aug 2008 | A1 |
20080200906 | Sanders et al. | Aug 2008 | A1 |
20080208147 | Argenta et al. | Aug 2008 | A1 |
20080234641 | Locke et al. | Sep 2008 | A1 |
Number | Date | Country |
---|---|---|
41 11 122 | Apr 1993 | DE |
43 06 478 | Sep 1994 | DE |
295 04 378 | Oct 1995 | DE |
0 358 302 | Mar 1990 | EP |
1 088 569 | Apr 2001 | EP |
1 219 311 | Aug 2002 | EP |
0 853 950 | Oct 2002 | EP |
488 232 | Jul 1938 | GB |
1 415 096 | Nov 1975 | GB |
1 549 756 | Mar 1977 | GB |
2 195 255 | Apr 1988 | GB |
2 235 877 | Mar 1991 | GB |
2 307 180 | May 1997 | GB |
2 329 127 | Mar 1999 | GB |
2 336 546 | Oct 1999 | GB |
2 244 531 | Jun 2000 | GB |
2 415 908 | Jan 2006 | GB |
1 762 940 | Jan 1989 | SU |
WO 8001139 | Jun 1980 | WO |
WO 8002182 | Oct 1980 | WO |
WO 8401904 | May 1984 | WO |
WO 8905133 | Jun 1989 | WO |
WO 9011795 | Oct 1990 | WO |
WO 9219313 | Nov 1992 | WO |
WO 9309727 | May 1993 | WO |
WO 9420041 | Sep 1994 | WO |
WO 9605873 | Feb 1996 | WO |
WO 0021586 | Apr 2000 | WO |
WO 03005943 | Jan 2003 | WO |
WO 03018098 | Mar 2003 | WO |
WO 03030966 | Apr 2003 | WO |
WO 03057070 | Jul 2003 | WO |
WO 03057071 | Jul 2003 | WO |
WO 03057307 | Jul 2003 | WO |
WO 03045492 | Aug 2003 | WO |
WO 03086232 | Oct 2003 | WO |
WO 03092620 | Nov 2003 | WO |
WO 03101508 | Dec 2003 | WO |
WO 2004018020 | Mar 2004 | WO |
WO 2005009488 | Feb 2005 | WO |
WO 2006015599 | Feb 2006 | WO |
WO 2006105892 | Oct 2006 | WO |
WO 2008020862 | Feb 2008 | WO |
WO 2008048481 | Apr 2008 | WO |
WO 2008048481 | Apr 2008 | WO |
Number | Date | Country | |
---|---|---|---|
20100010477 A1 | Jan 2010 | US |
Number | Date | Country | |
---|---|---|---|
61078838 | Jul 2008 | US |